Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome‐positive acute lymphoblastic leukemia

Tyrosine kinase inhibitor (TKI) administration after allogeneic hematopoietic stem cell transplantation (HSCT) may carry a survival benefit in Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL). Therefore, we investigated whether TKI prophylaxis for negative‐minimal residual dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Akahoshi, Yu, Nishiwaki, Satoshi, Mizuta, Shuichi, Ohashi, Kazuteru, Uchida, Naoyuki, Tanaka, Masatsugu, Fukuda, Takahiro, Ozawa, Yukiyasu, Takahashi, Satoshi, Onizuka, Makoto, Shiratori, Souichi, Nakamae, Hirohisa, Kanda, Yoshinobu, Ichinohe, Tatsuo, Atsuta, Yoshiko, Kako, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778639/
https://www.ncbi.nlm.nih.gov/pubmed/31402561
http://dx.doi.org/10.1111/cas.14167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778639/
https://www.ncbi.nlm.nih.gov/pubmed/31402561
http://dx.doi.org/10.1111/cas.14167

Ejemplares similares